Eris Lifesciences Ltd Share Price Today

Eris Lifesciences Ltd. Share Price

Overview

Eris Lifesciences Ltd. share price is currently ₹1,115.42, up by ₹1.65 (0.15%) from its previous closing price of ₹1,113.77. The share price has declined -12.73% over the past month and declined -29.13% over the past year. The stock's 52-week low and high are ₹1,089.56 and ₹1,718.17, respectively. Eris Lifesciences Ltd. has a market capitalisation of ₹ 15,880.00 Cr. The share price was last updated on 22 Oct 2026, 09:16 AM IST.

Actions	Ex-Date	Record-Date
DividendsInterim Dividend of 721% at ₹7.21/Share	29-May-2026	29-May-2026
DividendsInterim Dividend of 735% at ₹7.35/Share	13-Feb-2025	13-Feb-2025

Actions

Ex-Date

Record-Date

DividendsInterim Dividend of 721% at ₹7.21/Share

29-May-2026

DividendsInterim Dividend of 735% at ₹7.35/Share

13-Feb-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
HDFC Small Cap Fund - Regular Plan - Growth	64.65 Lac	64.65 Lac no change
HDFC Aggressive Hybrid Fund - Growth	24.60 Lac	24.60 Lac no change
Franklin India Small Cap Fund - Growth	22.34 Lac	23.92 Lac (7.1%)
Franklin India Flexi Cap Fund - Growth	14.10 Lac	14.18 Lac (0.54%)
DSP Small Cap Fund - Regular Plan - Growth	12.30 Lac	12.30 Lac no change

Mutual Fund Holder

Aug 26

Shares held

Sep 26

Shares held

HDFC Small Cap Fund - Regular Plan - Growth

64.65 Lac

no change

HDFC Aggressive Hybrid Fund - Growth

24.60 Lac

no change

Franklin India Small Cap Fund - Growth

22.34 Lac

23.92 Lac

(7.1%)

Franklin India Flexi Cap Fund - Growth

14.10 Lac

14.18 Lac

(0.54%)

DSP Small Cap Fund - Regular Plan - Growth

12.30 Lac

no change

VIJAY KUMAR GUPTA

20 Sep • 7:11 AM · SEBI-Registered Analyst

Title (60 chars): Eris Lifesciences Q1 FY27: GLP-1 leader

ERIS

Eris Lifesciences Limited reported Q1 FY27 results for the June 2026 quarter on 29 July. Revenue grew 13% and profit 14.5%, but the EBITDA margin missed guidance. Q1 FY27 numbers (consolidated): Revenue: Rs 873.25 crore, up 13% YoY from Rs 771.56 crore EBITDA: Rs 296 crore, up 7% YoY; margin 33.9% vs FY27 guidance 36 to 37% PAT: Rs 142.39 crore, up 14.5% YoY from Rs 125.10 crore; EPS Rs 10.28 DBF segment: up 14.2%; 7 of 10 therapies in double digits Semaglutide (GLP-1): 20% volume share, 14% value share; ranked first in generic semaglutide prescriptions Interim dividend Rs 7.21 per share The margin miss is structural. Biologics and insulin carry lower initial gross margins than legacy oral anti-diabetes; as they scale, margins are expected to recover. HALMED inspection findings from March 2026 have delayed European CDMO commercialisation. Eris Lifesciences [

ERIS

][***** shares closed at Rs 1,288.21 (18 Sep 2026, 03:29 PM IST), down 23 percent over one year, near the Rs 1,222 52-week low. P/E 27.6; sector P/E 44.64; PEG 0.38. My view: the GLP-1 thesis is intact — number-one rank in generic semaglutide prescriptions in the launch quarter. The issue is that biologics compress margins in the near term and HALMED delays the EU CDMO revenue that was part of the FY27 thesis. At 27.6x, PEG 0.38 vs sector 44x, the compressed multiple is either an opportunity or an early signal of structural margin pressure. FY27 margin exit rate is the test. Accumulate Rs 1,222 to 1,290; invalidation on a close below Rs 1,222; Rs 1,450 to 1,500 the resistance. Disclosure: Vijay Kumar Gupta, SEBI Registered Research Analyst, INH000020226, Vijay Gupta Advisory. SEBI registration and NISM certification do not guarantee performance or assure returns. Securities markets are subject to market risks. No holdings in the subject company.

Vimal K

28 May • 9:33 AM · SEBI-Registered Analyst

WATCH OUT FOR CORPORATE ACTIONS

Watch out for the Corporate actions today 29-May-2026 on the below mentioned stocks: - Life Insurance Corporation of India (LIC) : - Life Insurance Corporation of India 1:1 Bonus Issue (Investors receive 1 free additional share for every 1 share held). The Ex-Date and Record Date are both fixed for May 29, 2026. Bajaj Auto Ltd, GlaxoSmithKline Pharma, Torrent Pharmaceuticals, ERIS Lifesciences Ltd, ICICI Lombard GI, Home First Finance, and Bank of India will trade Ex-Dividend tomorrow the 29-May-2026.

BAJAJ-AUTO

TORNTPHARM

ERIS

ICICIGI

HOMEFIRST

BANKINDIA

Akhilesh Jat

20 May • 8:57 AM · SEBI-Registered Analyst

Earnings Alert: Stocks in Focus Ahead of Q4 Announcements

📊 Q4 Results Watch | Earnings Announcement Today Investors and market participants will closely track Q4 earnings today from: •

GRASIM

•

APOLLOHOSP

•

LENSKART

•

OLAELEC

•

BOSCHLTD

• !Dr Agarwals Eye Hospital •

ERIS

•

HCL-INSYS

•

HONAUT

•

IRB

•

JUBLFOOD

•

METROBRAND

•

WHIRLPOOL

Key management commentary on margins, demand outlook, capex, and FY27 guidance will remain in focus. Stay alert for earnings-driven volatility and sector-specific opportunities across the market. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

Vineet Chawla

3 May • 8:55 PM · SEBI-Registered Analyst

Swing Bullish Strategy – Eagle Momentum (Weekly)

BANDHANBNK

has been outperformed Nifty 500 over last 1 week. The Weekly Eagle Momentum strategy focuses on identifying stocks showing strong short-term relative strength compared to the broader market. It selects stocks that have outperformed the benchmark over the last 1 week, indicating strong buying interest and emerging momentum. Traders use this strategy to identify stocks that may continue their short-term upward momentum, making them suitable candidates for swing trades. Traders typically combine this with price structure, volume strength, and support levels to identify potential entries while maintaining disciplined risk management. Disclaimer - Investments in securities market are subject to market risks, read all the related documents carefully before investing.

Pyrifera Investment Advisors

20 Apr • 11:27 PM · SEBI-Registered Analyst

Eris Lifesciences Receives HALMED Inspection Findings; Minimal Operational Impact Expected

Eris Lifesciences has received inspection findings from Croatia's HALMED agency following a March 9–13, 2026 audit of its two Ahmedabad manufacturing units: Unit 1 (general liquid/dry powder injectables) and Unit 2 (betalactam dry powder injectables). The inspection identified procedural non-compliance observations requiring alignment with EU GMP standards under Directive 2017/1572. Eris is preparing its response and Corrective and Preventive Actions (CAPAs) for submission to HALMED. Operational Impact: Existing business: Expected to remain largely unaffected. European CDMO pipeline: Commercialization timelines may see delays pending remediation and re-approval. The company has committed to implementing necessary improvements and will request a follow-up inspection once corrective measures are complete to reinstate regulatory approvals for both facilities. While the findings underscore the rigorous scrutiny of EU-linked regulators, Eris's proactive remediation approach and strong domestic footprint should cushion near-term impact. The episode highlights the ongoing compliance challenges for Indian pharma exporters in regulated markets, but management's assurance of minimal disruption reinforces confidence in the company's quality systems and operational resilience.

ERIS

SFP RESEARCH

30 Mar • 12:31 PM · SEBI-Registered Analyst

Eris Lifesciences Ltd.

ERIS

s is a chronic‑focused branded‑generics company in cardio‑metabolic and related therapies. It operates with a pure‑India, high‑margin, specialty model. Acquisitions in derma/endocrine expand its therapy coverage. Risks are doctor‑coverage saturation and pricing pressure from larger chronic players.

Eris Lifesciences Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Eris Lifesciences Ltd. 👋

Expert Opinions

Frequently Asked Questions

What is the share price of Eris Lifesciences Ltd.?

What is the market cap of Eris Lifesciences Ltd.?

Should I buy Eris Lifesciences Ltd. stock now?

What is the 52 week high and low of Eris Lifesciences Ltd.?

Is the Eris Lifesciences Ltd. stock good to buy?

Is Eris Lifesciences Ltd. a good buy for the long term?

Is Eris Lifesciences Ltd. overvalued or undervalued?

What is the PE and PB ratio of Eris Lifesciences Ltd.?